Loading...
•
Jun 30, 2021
Orthofix Q2 2021 Earnings Report
Delivered accelerated topline growth sequentially and over pre-COVID levels.
Key Takeaways
Orthofix Medical Inc. reported a strong second quarter with net sales of $121 million, a 66% increase compared to the prior year. EPS was $0.12, and adjusted EPS was $0.32. The company is raising its full year 2021 revenue and adjusted EBITDA guidance.
Net sales of $121 million, up 66% compared to prior year and 5% compared to the second quarter of 2019
U.S. Spinal Implants net sales grew 56% compared to prior year and 37% over the second quarter of 2019
Strong performance from our U.S. M6-C™ artificial cervical disc and FITBONE® limb lengthening system with approximately $9 million in combined sales
Company raises full year 2021 revenue and adjusted EBITDA guidance
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.comGlobal Orthopedics Revenue
CapyFin.com Forward Guidance
The Company expects the following net sales results for the year ended December 31, 2021. Current net sales outlook is $468.0 to $474.0 million, adjusted EBITDA is $58.0 to $61.0 million and adjusted EPS is $0.74 to $0.82.
Positive Outlook
- Net sales year-over-year increase of 15.1% to 16.6% on a reported basis
- Adjusted EBITDA year-over-year increase of 21.8% to 28.1%
- Adjusted EPS year-over-year increase of 184.6% to 215.4%
Revenue & Expenses
Visualization of income flow from segment revenue to net income